BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

30 related articles for article (PubMed ID: 38613852)

  • 1. Considerable interlaboratory variation in PD-L1 positivity for head and neck squamous cell carcinoma in the Netherlands- A nationwide evaluation study.
    Hempenius MA; Koomen BM; Deckers IAG; Oosting SF; Willems SM; van der Vegt B
    Histopathology; 2024 Apr; ():. PubMed ID: 38606992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Research progress of microsatellite instability in head and neck squamous cell carcinoma].
    Guo Y; Cheng YL; Yang XX; Meng HX
    Zhonghua Bing Li Xue Za Zhi; 2024 Jun; 53(6):647-650. PubMed ID: 38825918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comment on "Betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study".
    Aragão HHR; Monteiro MA; Lopes NVA; Cunha JLS
    Oral Oncol; 2024 May; 152():106788. PubMed ID: 38574564
    [No Abstract]   [Full Text] [Related]  

  • 4. Betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study.
    Hong RL; Yen CJ; Lien MY; Cheng R; Su YW; Lin HN; Poon SL; Chien CY
    Oral Oncol; 2024 May; 152():106760. PubMed ID: 38520758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Pai SI; Cohen EEW; Lin D; Fountzilas G; Kim ES; Mehlhorn H; Baste N; Clayburgh D; Lipworth L; Resteghini C; Shara N; Fujii T; Zhang J; Stokes M; Wang H; Twumasi-Ankrah P; Wildsmith S; Khaliq A; Melillo G; Shire N
    J Transl Med; 2019 Dec; 17(1):429. PubMed ID: 31878938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spatial Intratumoral Heterogeneity Expression of PD-L1 Antigen in Head and Neck Squamous Cell Carcinoma.
    Hirshoren N; Al-Kharouf I; Weinberger JM; Eliashar R; Popovtzer A; Knaanie A; Fellig Y; Neuman T; Meir K; Maly A; Vainer GW
    Oncology; 2021; 99(7):464-470. PubMed ID: 33789303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comment on betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study.
    Sekar D
    Oral Oncol; 2024 May; 152():106800. PubMed ID: 38613852
    [No Abstract]   [Full Text] [Related]  

  • 9. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
    Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
    Front Immunol; 2020; 11():1721. PubMed ID: 33072064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck.
    De Meulenaere A; Vermassen T; Aspeslagh S; Huvenne W; Van Dorpe J; Ferdinande L; Rottey S
    Oral Oncol; 2017 Jul; 70():34-42. PubMed ID: 28622889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy.
    Paolino G; Pantanowitz L; Barresi V; Pagni F; Munari E; Moretta L; Brunelli M; Bariani E; Vigliar E; Pisapia P; Malapelle U; Troncone G; Girolami I; Eccher A
    Pathol Res Pract; 2021 Oct; 226():153605. PubMed ID: 34530257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy.
    Chen Y; Ding X; Bai X; Zhou Z; Liu Y; Zhang X; Yu J; Hu M
    Int Immunopharmacol; 2023 Jul; 120():110329. PubMed ID: 37207445
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.